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Certain febrile diseases are unaccompanied by infection or apparent hypersensitivity. In
myocardial infarction or pulmonary embolism, for example, fever has been attributed to
inflammation and/or tissue necrosis. Exogenous (microbial) pyrogens stimulate both human and
animal monocytes/macrophages to produce endogenous pyrogen (EP) in vitro. To determine if
plasma and cellular endogeneous mediators (EMs) of inflammation induced EP production,
human mononuclear cells (M/L) were incubated for 18 hours with varying amounts of EM and
thesupernates assayed for EP in rabbits. Neutrophils (PMNs), which do not generate EP and yet
are a feature of acute inflammation, were tested. Neither viable, phorbol myristic acetate-
stimulated PMNs nor sonicated PMNs, red blood cells, or M/L stimulated human monocytes to
produce EP. Human C3bandC5a, which mediate phagocytosis and chemotaxis, respectively, were
alsoinactive. Despite itschemoattractant properties, the synthetic peptide FMLP failed to induce
EP release. Since Poly I:Poly C (PIC: a synthetic, double-stranded RNA) is a potent pyrogen in
rabbits, we investigated PIC, as well as a native, single-stranded RNA (from E. coli) and DNA
(from calf thymus). None was active in vitro, and only PIC caused fever when given to rabbits
intravenously. In summary, we have been unable to find an endogenous activator of EP from
human monocytes to explain fevers associated with inflammation alone.
INTRODUCTION
Fever is a characteristic sign of inflammation whether it be due to infection, tissue
damage, or a hypersensitivity reaction. The pathogenesis offever in infectious diseases
has been attributed to certain microbial factors (such as LPS-endotoxin) that induce
monocytes or macrophages of the host to release endogenous pyrogen/interleukin-1
(EP/IL-1). Specialized cells in the anterior hypothalamus are acted upon by EP/IL-1
to initiate the peripheral changes (decreased heat loss and increased heat production)
that elevate body temperature [1]. Other exogenous pyrogens, including antigen-
antibody complexes or antigens and lectins (which appear to act indirectly via the
release of lymphokines), are also recognized as inducers of EP production. However,
the sequence ofevents by which inflammation causes fever, in the apparent absence of
infection or allergy, remains unclear. Recently, urate crystals have been reported to
release EP in vitro, suggesting one mechanism whereby an endogenous activator may
cause fever in gouty inflammation [2].
There are, however, other diseases often associated with fever such as myocardial or
pulmonary infarction, thrombophlebitis, and dissecting aneurysm for which there is no
known pyrogenic stimulus. Fever in these illnesses has generally been attributed to
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associated inflammation-a response to tissue injury that involves the coordinated
release ofmultiple endogenous agents [8].
In an attempt to identify the probable cause offever in such diseases, components of
the inflammatory process and associated by-products of tissue disruption were
evaluated for their capacity to activate human monocytes to release EP in vitro.
METHODS
General
Previously employed methods were utilized to insure that all procedures, glassware,
and reagents were sterile and pyrogen-free [3].
Pyrogen Assay
Techniques for assay of EP in trained rabbits were the same as reported previously
[3]. Since rabbits become sensitized and react with fever when given foreign antigens
after repeated intravenous inoculations, new groups of animals were used at weekly
intervals. The fever response was expressed as the maximum temperature increase
from baseline occurring within 60 minutes following injection. Significance of mean
responses was calculated by the appropriate t-test.
Preparation ofCells andSerum
Human venous blood (100-200 ml) was collected from normal volunteers with
heparinized (10 ,u/ml) syringes (heparin sodium injection [10,000 4/ml]: Eli Lilly and
Company, Indianapolis, IN). Each 25 ml of blood was diluted with 15 ml Eagle
minimal essential media ([MEM] Auto-Pow; Flow Laboratories, Inc., Rockville, MD)
containing penicillin/streptomycin ([5,000 g/ml/5,000 ,u/ml] Gibco Laboratories,
Grand Island, NY) and 1 ml of heparin (1,000 ,/ml). Leukocytes (enriched for
monocytes and lymphocytes) werecollected bycentrifugation through Ficoll-Hypaque
(Ficoll; Pharmacia Fine Chemicals, Piscataway, NJ; Hypaque sodium [50 percent]:
Winthrop Laboratories, New York, NY) density gradients [4].
Dextran (100,000-200,000 molecular weight; ICN Nutritional Biochemicals,
Cleveland, OH) sedimentation with hypotonic lysis oferythrocytes (RBCs) was used
to obtain neutrophils (PMNs) [5].
Both monocyte-lymphocyte (M/L) fractions and PMNs were washed twice in
MEM and the pellets resuspended in MEM with either 10 percent fetal bovine sera
([FBS], Flow Laboratories, Inc.) or 10 percent autologous normal human sera (NHS)
except for the Poly I:Poly C experiments where aliquots were incubated with MEM
alone. Human blood for sera was obtained by venipuncture, allowed to clot for two
hours at 370C, and centrifuged at 1,800 rpm x 15 minutes. To abolish complement
activity, sera was then placed in a 560C stationary water bath for 15 minutes.
Cell counts were determined with a Coulter Particle Counter (model Zf; Coulter
Electronics, Inc., Rockville, MD). Viability was .90 percent by eosin red exclusion.
M/L fractions contained an average of 30 percent M, 68 percent L, and 1-2 percent
PMNs. Each aliquot contained two or more doses of 3-5 x 106M with 6-10 x 106 L
each in a volume of4 ml/dose unless otherwise stated.
Polymyxin B
Polymyxin B (PMB) (50,000,/ml) was diluted in physiologic saline to 2,000 ,u/ml
and added to each dose containing a non-cellular experimental activator (i.e., FMLP,
PMA, nucleic acids, C5a, and C3b to prevent false positive results secondary to
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endotoxin [6]). When added to either complement or FMLP, one batch of PMB
regularly activated cells to produce EP. Since further tests with other batches did not
confirm these findings, they have been omitted from the results.
Incubation
Aliquots of M/L suspended in MEM alone or MEM/NHS were placed in 30 ml
tissue culture flasks (Falcon Labware, Div. Becton, Dickinson and Co., Oxnard, CA)
and various activators/EMs added. Each experiment had a "negative" control (M/L
in MEM with sera) and a "positive" control ofeither heat-killed staphylococci (20:1,
bacteria:phagocytes) or 1 ng lipopolysaccharide (LPS) [7]. Exogenous pyrogens
(staphylococci and LPS) were usually added with each EM toconfirm that these M/L
cultures were capable of EP release. All preparations were incubated for 18 hours at
370C in 5 percent C02; the aliquots were then centrifuged, and the supernates assayed
for endogenous pyrogen (EP). Cell viability after 18 hours incubation was >85
percent. The samples werecultured for48 hours in thioglycolate broth, and, in the rare
instance ofcontamination, the results were discarded.
Endogenous Materials
Neutrophils (PMNs) PMNs were separated from human blood by dextran
sedimentation and hypotonic lysis of erythrocytes. PMN fractions contained an
average of 86 percent PMNs, 4 percent L, 0.2 percent M, and 10 percent eosinophils.
3 x 107 PMNs were suspended in 2 ml MEM/NHS. Sonication (Sonifer, Model 200,
Branson Sonic Power Co., Danbury, CT) was used for PMN disruption. Before each
experiment the sonicator probe was wrapped in foil and baked in an oven at 2400C to
insure that it was pyrogen-free. After attachment, the probe was rinsed with 300 ml
sterile sodium chloride irrigation solution containing 10 ml penicillin-streptomycin
([5,000 ,/ml/5,000 ,u/ml]). As a control, 2 ml MEM/NHS alone was sonicated first
(10 seconds x 3 at 30 watts) and incubated with M/L. Theexperimental cells (viable
or sonicated) were incubated with aliquots of M/L cells and assayed for EP
production.
Phorbol Myristic Acetate (PMA) PMA (Consolidated Midland Co., Brewster,
NY) was reconstituted as 2.5 mg PMA per 1 ml ofDMSO, diluted to 200 mg/ml in
DMSO, and stored at -700C. Prior to use, it was prepared as 100 ng/ml sodium
chloridesolution. As acontrol, 100ng PMA wasincubated with 3.0 ± 0.3 x 106 M and
8.87 ± 1.6 x 106 L in 4 ml MEM/NHS per dose and assayed for EP-inducing
activity.
To stimulate the respiratory pathway and release the metabolites and primary
granules of PMNs, PMA was added (in dosages of 200 ng/2.5 x 107 cells) and
incubated in a stationary water bath for ten minutes at 370C. To remove excess PMA,
the cells were centrifuged and resuspended in fresh MEM/NHS. Hydrogen peroxide
production by PMA-stimulated PMNs was measured by extinction of scopoletin
fluorescence toverify that cell stimulation had occurred [8].
Complement (C3b andC5) A mixtureofpurified human complementfragments
(C3band C5a) werekindlysupplied by Dr. Donald Kreutzer (University ofConnecticut
School of Medicine, Farmington, CT). The ED50, defined as the concentration of the
complement factor equivalent to one-halfits maximum chemotactic response [9], was
16.7 microliters (,gl). Three concentrations/activities were used: 36 x (600,ul). 48 x
(800 ,ul), and 72 x (1,200 ,ul) the ED50. Each complement concentration was added to
106M and 4-6 x 106 L, incubated, and assayed.
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N-Formyl-methionyl-leucyl-phenyalanine (FMLP) FMLP (Haemachem, Inc.
Lot No. 81B1) was provided by Julia Metcalf (Yale University, New Haven, CT) at a
concentration of 10-2M in DMSO. The stock solution was diluted with physiologic
saline to produce either a final concentration of: (a) 10-8M, at which concentration
Showell et al. have demonstrated the chemoattractant properties ofFMLP [10]; or (b)
10-5M, at which concentration Hatch et al. demonstrated that FMLP triggers a burst
of oxidative metabolism leading to the generation of superoxide [11]. Each FMLP
concentration was added to 2.6 ± 0.3 M and 5.65 ± 3.0 x 106 L, incubated, and
assayed.
Red Blood Cells (RBCs) As previously stated, PMNs were processed and the
RBCs were removed from the remaining pellet and diluted intovarious concentrations
(refer to Table 3) using sodium chloride irrigation solution in 1 ml aliquots. Disruption
of RBCs was by sonication as described above. An aliquot of disrupted RBCs
equivalent to 4 x i07-i x 109 whole RBCs was added to 3 x 106M, incubated, and
assayed.
Mononuclear Cells (M/L) M/L were obtained by processing with Ficoll-
Hypaque density gradients. Sonication was performed as described above and cell
contents equivalent to 2 x 107M and 2.7 x 107 lymphocytes in 2 ml per dose were
incubated with viable M/L and assayed.
Nucleic Acids
1. Poly I: Poly C-Poly L-lysine (Poly I:C), a synthetic, double-stranded RNA,
was kindly supplied by Dr. John Kirkwood (Yale University, New Haven,
CT). Stock Solution (Flow Lot 3, 111379 CMC 0.5 percent, Lot cc-134)
contained 2 mg/ml Poly I:C and 1.5 mg/ml Poly L-lysine. The Poly I:C stock
solution was diluted to a dose equivalent to 40 ,ug/ml sodium chloride
solution. Each dose was added to 4 x 106M and 6.6 x 106Ly, incubated, and
assayed.
2. Short-chain nucleic acids-Short-chain calf thymus DNA (1 mg/ml) and
E. coli-derived RNA (10 mg/ml), kindly provided by Dr. Joan Steitz (Yale
University School of Medicine, New Haven, CT), were supplied as stock
solutions and diluted with physiologic sodium chloride solution to concentra-
tions of 0.3 mg/ml RNA, 0.5 mg/ml RNA, and 0.2 mg/ml DNA. Each of
these mediators was then added to make one or more dosescontaining 4 ml of
MEM with 5.4 x 106M and 1.04 x I07 L, incubated, and assayed.
3. Long-chain nucleic acids-100 ,ug of calf thymus DNA (in 3 ml sodium
chloride solution) and 100 ,ig of E. coli-derived RNA (in 2 ml sodium
chloride solution) were given intravenously to determine their pyrogenicity
and their capacity to induce EP production in vivo.
RESULTS
One aliquot (two doses) ofeach substance to beevaluated was incubated with one or
two known activators (staph and LPS) to insure that the monocytes were not inhibited
from releasing EP.' In all cases these positive controls produced a mean febrile
response of0.30C or greater.
'Three additional agents, prostoglandin El, fibronectin (plasma fibronectin) kindly supplied by Dr. Philip
J. Spagnuolo (Case Western Reserve University,OH), and platelet activating factor (PAF) were alsotested,
in doses which have pharmacologic effects, and none was capable ofstimulating EP release.
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TABLE 1
Release of Endogenous Pyrogen from Human Monocytes Incubated with Various Agents in Vitro
(Agents: PMNs and PMA)
Activator T(oC)b No. Trials
Sonicated medium (MEM) 0.01 ± 0.0 11
Sonicated PMNs (3 x 10') 0.02 ± 0.0 13
Sonicated PMNs + LPS (1 ng) 0.34 ± 0.09 5
Sonicated PMNs + Staphylococci (20:1) 1.50 ± 0.30 2
Viable PMNs 0.0 2
LPS (1 ng) 0.88 ± 0.08 6
Staphylococci (20:1) 1.40 ± 0.20 2
PMA (100 ng)a 0.04 ± 0.0 10
PMA (100 ng) + LPS (I ng) 0.88 ± 0.12 3
LPS (1 ng) 1.43 ± 0.09 3
PMA-stimulated PMNs (3 x 107) 0.0 2
Viable PMNs 0.0 2
aPolymyxin B (2,000 At/dose) was added to the experimental aliquot prior to incubation to remove any
contaminating endotoxin due to the agent's non-sterile preparation.
bMean (± SEM) febrile responses of rabbits to EP released by monocytes incubated 18 hours with each
agent
Neutrophils (PMNs)
Neither intact, activated, or disrupted PMNs were capable of stimulating EP
release from monocytes (Table 1).
Complement Fragments (C3b andC5a)
The human complement fragments ofC3b and C5a were not mediators of EP release
in vitro (Table 2).
FMLP
Neither concentration of 10-5M nor 10-8M was capable of stimulating EP release
from monocytes (Table 2). Similarly FMLP (10-8M) was nonpyrogenic when given
intravenously.
Sonicated Cells
Neither sonicated RBCs nor M/L stimulated EP release (Table 3).
Nucleic Acids
Multiple trials revealed that mammalian DNA and bacterial RNA as well as Poly
I:Poly C were incapable of stimulating human monocytes to produce EP in vitro
(Table 4).
Long-chain RNA and DNA were also injected intravenously (one recipient each)
but did not evoke any change in temperature suggesting in vivo EP production
(Table 4).
DISCUSSION
The inflammatory reaction has been defined as a series of multiple interlocking
components. Injury of any type induces an immediate acute inflammatory response
with two main effects: (a) exudation offluid containing plasma and tissue mediators of
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TABLE 2
Release of Endogenous Pyrogen from Human Monocytes Incubated with Various Agents in Vitro
(Agents: Complement By-Products [C3b and Cs.] and FMLP)
Activator T(oC)b No. Trials
C3b and C58 (600 Il)' 0.04 ± 0.03 6
C3b and Cs, (800lil)' 0.0 2
C3b andCs. (1,200 MA) 0.15 ± 0.05 2
LPS (1 ng) 0.63 ± 0.02 3
FMLP (10-8M)a 0.02 5
FMLP (10-M) + LPS (1.5 ng) 0.78 ± 0.08 2
LPS(I ng) 0.72± 0.13 3
FMLP (10-5M)a 0.0 3
FMLP (10-8M)c 0.0 6
"Polymyxin B (2,000 M/dose) was added to the experimental aliquot prior to incubation to remove any
contaminating endotoxin due to the agent's non-sterile preparation.
bMean (± SEM) febrile responses of rabbits to EP released by monocytes incubated 18 hours with each
agent
cResponse ofrabbits to injection ofagent in 4 ml ofsaline
inflammation, and (b) exudation of white blood cells, initially polymorphonuclear
leukocytes and later mononuclear forms with their associated release of cell products
[12]. Subsequently, factors in the exudate induce healing. Myocardial and pulmonary
infarction, which are both associated with fever, result in tissue death and necrosis,
thereby activating the inflammatory response in vivo. Many ofthe pathways by which
infection produces inflammation and fever have been defined. However, no component
of the inflammatory response itself has been implicated as an endogenous inducer of
EP release and hence offever.
As the characteristic cell present in acute inflammation, the PMN, no longer
recognized as producing EP, is an obvious choice to be tested as a possible EM of EP
release [13,14]. PMNs contain cytoplasm, nucleus, and azurophilic (primary) and
specific (secondary) granules and selectively release granule-associated (lysosomal)
enzymes when appropriately stimulated. These lysosomal enzymes are capable of
producing many of the features of the acute inflammatory response [15]. Therefore,
both sonication of PMNs and PMA-induced primary granule release were utilized to
produce breakdown of the PMN into its cellular and metabolic components. In our
experiments with human bloodcells, noneofthe PMN fractionsobtained bysonication
or induced by PMA was pyrogenic or an inducer ofEP release. Although Herion et al.
[16] reported that lysosomal fractionsofrabbit (but not human) blood cells and rabbit
exudate cells were pyrogenic, the findings in regard to rabbit cells were not confirmed
in a later study by Hahn et al. [17]. Positive controls in which LPS or staphylococci
were added to samples containing PMN fractions verified that stimulation of EP
release from monocytes was possible. It is interesting to note that EP production by
LPS but not staphylococci was reduced by about one-halfin the presence ofsonicated
PMNs (Table 1). Collins and Wood have similarly shown that lysosomes and
lysosomal basic proteins of leukocytes diminish in vitro the pyrogenic and lethal
actions ofendotoxin (LPS) [18].
Phorbol myristic acetate (PMA) has been reported to be a potent inducer of
lymphocyte-activating factor (LAF) [19]. Through theworkofseveral investigators, it
now appears that LAF and EP are similar, if not the same, molecule [20,21].
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TABLE 3
Release of Endogenous Pyrogen from Human Monocytes Incubated with Various Agents in Vitro
(Agent: Sonicated RBCs and M/L)
Activator T(0C)' No. Trials
Sonicated RBCs (4 x 10) 0.0 7
Sonicated RBCs (1 x 108) 0.01 7
Sonicated RBCs (1 x 108) + LPS (1 ng) 0.52 ± 0.06 3
Sonicated RBCs (1 x 10') 0.05 ± 0.05 2
Sonicated RBCs (1 x 10') + LPS (1 ng) 0.70 ± 0.23 3
Sonicated M/L 0.0 2
Sonicated M/L + LPS (1 ng) 1.0 1
LPS(1 ng) 1.0 ± 0.0 2
'Mean (± SEM) febrile responses of rabbits to EP released by monocytes incubated 18 hours with each
agent
Therefore, it is necessary to discuss the lack of EP release in our data when cells were
incubated with PMA. The addition of polymxyin-B (PMB) in our experiments may
have inactivated contaminating LPS and thus removed the true stimulus (LPS) to EP
(and the previously reported LAF) release [6]. However, a more likely explanation is
provided by the recent observation that PMA binds to unknown serum, cellular, and
otherproteins toproduce itsmitogenic effects (bydirectlystimulating IL-2 rather than
IL-1 (LAF) release as previously suggested [22,23]. This PMA-protein complex is
nonpyrogenic in rabbits [23] and, as we have found here, is not an inducer of EP
(LAF).
C3b and Cs., activated by-products of the complement cascade, are important in
promoting certain aspects of inflammation such as chemotaxis, phagocytosis,
increased vascular permeability, and histamine release. The significance oftesting the
complement cascade by-products (C3b and C5U) for their ability to induce EP
production as a side effect of inflammation rests on the following: (1) chemotactic C3
fragments have been found in recently infarcted heart muscle [24] and in synovial
fluids of inflammatory non-rheumatoid joint disease [25]; (2) chemotactic C5
fragments are present in synovial fluids of rheumatoid arthritis [25]; and (3)
chemotactic factors and substances enhancing phagocytosis are regularly generated in
any type ofinflammatory process.
Although Goodman et al. have reported that C5 is an inducer of LAF production
[26], human fragments C3band C5a failed toproduce EPin the presenceofPMB in our
experiment. Again it is clear that the validity of EP/LAF production may require
reinvestigation of earlier reports where the possibility ofendotoxin (LPS) contamina-
tion has not been excluded [27]. In our work, both C5, and C3b were potent inducers of
EP in vitro unless PMB was added.
The stimulation of PMN random locomotion, chemotaxis, lysosomal enzyme
release, and the generation ofsuperoxide (02-) are some ofthe activities ofsynthetic
N-formylmethionyl peptides including N-formyl-methionyl-leucyl-phenyalanine
(FMLP) [10,11]. These activities are responses of phagocytic cells (both PMNs and
M) to multiple stimuli and are commonly present during the inflammatory process.
FMLP combines its chemotactic properties with the ability to trigger a burst of
oxidative metabolism, thereby simulating the natural activities of C58. As Table 2
demonstrates, the natural chemoattractant C5, and.FMLP were incapable of provok-
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TABLE 4
Release of Endogenous Pyrogen from Human Monocytes Incubated with Various Agents in Vitro
(Agents: Synthetic and Natural Nucleic Acids)
Activator T(OC)a No. Trials
PolyI: Poly C (40,g) 0.0 3
LPS (I ng) 1.17 ± 0.16 3
Short-Chain Nucleic Acids:
E. coli-derived RNA (0.3 mg) 0.03 ± 0.0 4
E. coli-derived RNA (0.5 mg) 0.11 ± 0.04 4
Calfthymus DNA (0.2 mg)b 0.10 ± 0.0 2
Long-Chain Nucleic Acids:
E. coli-derived RNA (100Ag)b 0.0 1
Calfthymus DNA (100,g)6 0.0 1
'Polymyxin B (2,000 ;i/dose) was added to the experimental aliquot prior to incubation to remove any
contaminating endotoxin due to the agent's non-sterile preparation.
bResponse ofrabbits to agent injected intravenously
ing EP release. Thus it appears from these data that neither of these agents, despite
having receptors on monocytes, is responsible for producing fever with inflammation
alone.
The synthetic, double-stranded RNA, Poly I:Poly C, was reported to be a potent
pyrogen in rabbits [28]. Natural DNA and RNA are nuclear contents released with
cellular disruption, but they have never been investigated for their ability to produce
EP. In general, the nucleotide sequence of DNA is both the source ofinformation for
the synthesis of proteins and the chemical basis of heredity. RNA functions as a
template for genetic information and protein synthesis.
In 1970 Nordland et al. [28] reported that human sera (and plasma) and, to a lesser
extent, calf sera had an inhibitory effect (due, presumably, to an RNAase) on the
pyrogenicity of Poly I:Poly C. Therefore, all our experiments with nucleic acids were
performed in MEM alone. The results (Table 4) suggest that neither synthetic nor
natural nucleic acids stimulate EP release from human monocytes in vitro even in the
absence ofthese serum inhibitors.
In a review of24 cases ofacute hemolytic anemia ofvarious etiologies, Wallenstein
and Aggeler describe 13 patients with temperatures of 380C or higher for which no
cause could be found [29]. In similar fashion, Hirst et al. reviewed 505 cases of
dissecting aneurysm and found fever higher than 380C in 23.6 percent of the patients
and higher than 390C in 7.9 percent [30]. Despite features common to both, for
example fever and red blood cell (RBC) disruption and hemolysis, the mechanisms by
which acute nonimmune hemolytic anemia anddissectinganeurysms producefeverare
unknown. These characteristics suggested that sonicated/disrupted RBCs might
contain endogenous activators of EP release. As Table 3 demonstrates, dosages up to
1 x 109 sonicated RBCs failed togenerate EP from monocytes, making itunlikely that
this stimulus alone is responsible for producing fever in clinical situations where there
is nonimmune hemolysis or sequestration ofblood in tissues or cavities.
CONCLUSION
In 1979, Atkins and Bodel discussed several disease categories and the frequency
with which they were associated with fever [31]. They concluded that "clinical fever
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seems clearly associated with those diseases in which inflammation, in one form or
another, plays a dominant role." In infectious diseases, for example, the role of
phagocytosis and/or endotoxin is well established. The endogenous agents and
synthetic materials studied in this report were chosen for their known involvement in
the inflammatory process and/or therefore possible role as EP-producing stimuli.
By 1968 Bodel and Hollingsworth [32] had described a pyrogen (resembling EP) in
thejoint fluid ofpatients with rheumatoid arthritis. In 1983 Wood et al. [33] reported
small quantities of a molecule similar to IL-1 from the joint fluids of patients with
rheumatoid arthritis, psoriatic arth,itis, Reiter's syndrome, osteoarthritis, gout, and
traumatic arthritis. In certain systemic collagen vascular diseases (systemic lupus
erythematosus, Still's disease-juvenile rheumatoid arthritis) fever is commonly
prominent and autoimmunity with associated antigen (Ag)-antibody (Ab)-comple-
mentcomplexes mayplay a significant role in thepathogenesis offever as well as other
features ofthese illnesses.
Ag-Ab complexes alone do not stimulate EP release in vitro; however, when
complement is added, the total complex can induce EP production [34]. Our work
suggests thatcomplement factors will not evoke EP release. Complement may thus act
as an essential cofactor for endogenous Ag-Ab complexes which then are capable of
inducing EP production. Consistent with this hypothesis, injected complexes (in
Ag-excess) were markedly less pyrogenic in rabbits which had been decomplemented
by cobra venom [35].
Cellular debris, including nucleic acids, is also a major component ofthe inflamma-
tion process. Lysosomal and bactericidal components ofphagocytic cells as well as the
by-products ofactivated lymphocytes are all present at the siteoftissue injury. Febrile
clinical conditions associated with tissue injury and often sterile inflammation include
multiplepulmonaryemboli, thrombophlebitis, pancreatitis, myocardial infarction, and
dissecting aneurysms. The cellular subfractions ofdisrupted PMNs, M/L, and RBCs
that were studied suggest that none of these components alone is the cause of fever
associated with sterile inflammation and/or tissue necrosis. Whether multiple factors
are required together to stimulate EP production remains to be determined.
Both histamine and serotonin (5-hydroxytryptamine) are vasoactive amines
released from mast cells and platelets during acute allergic inflammation. We did not
investigate these agents which, like thekinins, may produce hypotension and dramatic
changes in vascular tone and permeability when given in large doses. With the
exception ofsystemic mastocytosis, where fever is occasionally present as a prominent
finding [36], most diseases in which these agents are released are not characteristically
febrile.
Ryan and Majno [12] have defined inflammation as a response of living tissue to
local injury which leads to accumulation ofblood cells and fluids, a process presumably
selected in evolution as a defense against infection. In those febrile diseases associated
with sterile, nonallergic inflammation, the "invader" may be some cellular by-product
of tissue damage which the body does not recognize as "self." Production of Ag-Ab
complexes with fixation ofcomplement may then stimulate monocytes to produce EP
and hence fever. One argument against autosensitization as the mechanism of fever
production in such states, however, is the rapid onset offever that occurs, often within
hours, after trauma, thrombophlebitis, or infarction.
Although the endogenous stimuli to EP production in acute sterile inflammation
thus remain unidentified, physicians have long been aware that fever and inflamma-
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tion are closely associated [37]. Studies in ferrets [38] and, more dramatically, in
poikilothermic lizards [39] indicate that fever is not only a product of inflammation,
but, in turn, directs and accelerates the inflammatory response to the site of the
infection (presumably by the generation of various chemotactic stimuli) and thereby
limits its spread. Only now are we beginning to discover the number and diversity of
interrelated phenomena that are controlled by IL-1 and that have presumably
contributed to evolutionary aspects ofsurvival [40].
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